Philmore Robertson Jr
Overview
Explore the profile of Philmore Robertson Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Darwish M, Nunez R, Youakim J, Robertson Jr P
Clin Drug Investig
. 2023 Nov;
44(1):21-33.
PMID: 38017349
Background And Objective: Trofinetide is the first drug to be approved for the treatment of Rett syndrome, a neurodevelopmental disorder. The purpose of the study is to fully characterize the...
2.
Li A, Cui D, Yu E, Dobson K, Hellriegel E, Robertson Jr P
Xenobiotica
. 2018 Feb;
49(3):302-312.
PMID: 29473769
1. Aldehyde oxidase (AO enzymes)-mediated oxidation predominantly occurs at a carbon atom adjacent to the nitrogen on aromatic azaheterocycles. In the current report, we identified that AO enzymes oxidation took...
3.
Bond M, Rabinovich-Guilatt L, Selim S, Darwish M, Tracewell W, Robertson Jr P, et al.
Clin Drug Investig
. 2017 Sep;
37(12):1153-1163.
PMID: 28948482
Background And Objectives: Food intake can alter the pharmacokinetics of certain medications, including changes in their oral bioavailability, which is of particular concern for extended-release (ER) opioids because of the...
4.
Darwish M, Bond M, Ma Y, Tracewell W, Robertson Jr P, Webster L
Pain Med
. 2016 Jun;
18(1):61-77.
PMID: 27330154
Objective: To compare the oral abuse potential of hydrocodone extended-release (ER) tablet developed with CIMA ® Abuse-Deterrence Technology with that of hydrocodone immediate release (IR). Design: Randomized, double-blind, placebo-controlled, crossover...
5.
Nijenhuis C, Hellriegel E, Beijnen J, Hershock D, Huitema A, Lucas L, et al.
Invest New Drugs
. 2016 May;
34(5):565-74.
PMID: 27221729
Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and...
6.
Darwish M, Yang R, Tracewell W, Robertson Jr P, Bond M
Clin Pharmacol Drug Dev
. 2016 May;
5(2):141-9.
PMID: 27138027
Two open-label, single-dose, parallel-group studies assessed effects of renal and hepatic impairment on the pharmacokinetics of a hydrocodone extended-release (ER) formulation developed with the CIMA Abuse-Deterrence Technology platform. Forty-eight subjects...
7.
Nijenhuis C, Lucas L, Rosing H, Robertson Jr P, Hellriegel E, Schellens J, et al.
Xenobiotica
. 2016 Mar;
46(12):1122-1132.
PMID: 26998885
Omacetaxine mepesuccinate (hereafter referred to as omacetaxine) is a protein translation inhibitor approved by the US Food and Drug Administration for adult patients with chronic myeloid leukemia with resistance and/or...
8.
Darwish M, Bond M, Yang R, Tracewell W, Robertson Jr P
Clin Drug Investig
. 2015 Sep;
35(10):645-52.
PMID: 26369654
Background: Greater drug content requirements for extended-release (ER) opioids necessitate greater protection against dose dumping. Hydrocodone ER employs the CIMA(®) Abuse-Deterrence Technology platform, which provides resistance against rapid release of...
9.
Darwish M, Bond M, Hellriegel E, Robertson Jr P, Chovan J
Cancer Chemother Pharmacol
. 2015 Apr;
75(6):1143-54.
PMID: 25829094
Purpose: Bendamustine is a unique alkylating agent indicated for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B cell non-Hodgkin's lymphoma. Despite the extensive experience with bendamustine, its pharmacokinetic...
10.
Darwish M, Yang R, Tracewell W, Robertson Jr P, Bond M
Clin Drug Investig
. 2015 Mar;
35(5):291-7.
PMID: 25813216
Background And Objective: This open-label, crossover study evaluated the dose proportionality of a hydrocodone extended-release (ER) tablet employing the CIMA(®) Abuse-Deterrence Technology platform. Methods: Healthy volunteers were randomized to receive...